Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Friday, April 28, 2017

Cannabis use and outcomes in patients with aneurysmal subarachnoid hemorrhage

Another biased report. It is far more likely than these people are self treating themselves with marijuana and that use has zero to do with the progression or cause of the disease. But Big Pharma doesn't want an easily available and grown intervention to decrease their profits. So the demonization continues.

My 13 reasons for marijuana use post-stroke.  

But don't listen to me, I have absolutely no medical training. And since I'm stroke-addled my reasoning skills are non-existent. I will get some after my next stroke even if I have to travel to  one of these states or Uruguay or Netherlands or North Korea and soon Canada.

This animated map shows where marijuana is legal in the US
Behrouz R, et al.
The objective was to evaluate the relationship between cannabis use and outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The authors offer preliminary data that CB+ is independently associated with delayed cerebral ischemia and possibly poor outcome in patients with aSAH. The findings add to the growing evidence on the association of cannabis with cerebrovascular risk.


  • Records of consecutive patients admitted with aSAH between 2010 and 2015 were reviewed.
  • Clinical features and outcomes of aSAH patients with negative urine drug screen and cannabinoids-positive (CB+) were compared.
  • Regression analyses were used to assess for associations.


  • The study group consisted of 108 patients; 25.9% with CB+.
  • Delayed cerebral ischemia was diagnosed in 50% of CB+ and 23.8% of urine drug screen negative patients (P=0.01).
  • CB+ was independently associated with development of delayed cerebral ischemia (odds ratio, 2.68; 95% confidence interval, 1.03-6.99; P=0.01).
  • A significantly higher number of CB+ than urine drug screen negative patients had poor outcome (35.7% versus 13.8%; P=0.01).
  • In univariate analysis, CB+ was associated with the composite end point of hospital mortality/severe disability (odds ratio, 2.93; 95% confidence interval, 1.07-8.01; P=0.04).
  • However, after adjusting for other predictors, this effect was no longer significant.

No comments:

Post a Comment